Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2021 | $2.98B | $306.60M | $3.35 |
| 2020 | $2.85B | $-234.30M | $-2.56 |
| 2019 | $3.19B | $129.10M | $1.42 |
| 2018 | $2.25B | $99.40M | $1.09 |
| 2017 | $1.71B | $188.93M | $2.12 |
Social Signal Score
Earnings
Typical surprise +39.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 28$0.86 vs $0.68beat
- Thu, Aug 12$1.11 vs $0.48beat
- Thu, Apr 29$0.53 vs $0.33beat
- Thu, Feb 4$3.13 vs $2.06beat
- Thu, Nov 5$1.04 vs $0.17beat
- Thu, Aug 13$0.14 vs $0.29miss
Estimates and results for MDP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MDP's reported EPS growth of 12.1% a year over 4 years.
- EPS in 5 years
- $5.94
- Implied price
- $77.20
- Return from $59.07
- 5.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $38.38 — -35.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| 2.1% | -10.7% | -7.1% | -3.9% | -1.1% | 1.4% |
| 7.1% | -6.4% | -2.5% | 0.8% | 3.7% | 6.3% |
| 12.1% | -2.0% | 2.0% | 5.5% | 8.6% | 11.3% |
| 17.1% | 2.4% | 6.6% | 10.2% | 13.4% | 16.3% |
| 22.1% | 6.8% | 11.1% | 14.9% | 18.2% | 21.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- Newsmarketbeat.com·3d ago·Positive
Medexus Pharmaceuticals Q1 Earnings Call Highlights Medexus Pharmaceuticals TSE: MDP reported higher first-quarter fiscal 2027 revenue and adjusted EBITDA, supported by continued growth for GRAFAPEX and a stronger contribution from IXINITY, while management maintained its full-year outlook for the recently launched transplant-conditioning product.
View source ↗ - Newsyoutube.com·7d ago·Negative
Credit Card Balances at Pace with Inflation: Whitney Meredith Whitney, CEO of Meredith Whitney Advisory Group, joins Scarlet Fu and Tom Keene on "Bloomberg Money." They discuss how many Americans are living payday to payday as well as how consumers are utilizing their credit cards.
View source ↗